Johnson & Johnson shares edged lower in post-market activity Monday, falling 0.6% to $238.64 as healthcare stocks broadly retreated. The stock traded between $237.04 and $240.74 during the regular session with approximately 9.4 million shares changing hands.
The healthcare sector's weakness contrasted with broader market strength. The SPDR S&P 500 ETF gained 0.5%, while the Invesco QQQ Trust advanced 0.8%. The Health Care Select Sector SPDR Fund declined 0.9%, reflecting the sector's underperformance.
Johnson & Johnson management is scheduled to participate in the Barclays Global Healthcare Conference on March 10. The company will host a fireside chat at 11:30 a.m. Eastern Time, with a webcast available through its investor relations website and a replay posted approximately 48 hours later.
The company recently reported fourth-quarter sales of $24.6 billion and adjusted earnings of $2.46 per share. For 2026, Johnson & Johnson projects sales between $100.0 billion and $101.0 billion, with adjusted earnings per share expected to range from $11.43 to $11.63.
Legal challenges continue to present headwinds. The company confronts more than 67,500 lawsuits related to its talc-based products, which it maintains are safe and do not cause cancer. Last week, a New Jersey appeals court removed a plaintiffs' firm from state cases due to an ethics violation, though the firm intends to appeal the decision.
Investors should note the company's upcoming dividend payment. The board declared a quarterly dividend of $1.30 per share, payable on March 10 to shareholders of record as of February 24.
